Nerve grafting for peripheral nerve injuries with extended defect sizes

Tim Kornfeld · Peter M. Vogt · Christine Radtke

Received: 21 July 2018 / Accepted: 21 November 2018 / Published online: 13 December 2018
© The Author(s) 2018

Summary Artificial and non-artificial nerve grafts are the gold standard in peripheral nerve reconstruction in cases with extensive loss of nerve tissue, particularly where a direct end-to-end suture or an autologous nerve graft is inauspicious. Different materials are marketed and approved by the US Food and Drug Administration (FDA) for peripheral nerve graft reconstruction. The most frequently used materials are collagen and poly(DL-lactide-ε-caprolactone). Only one human nerve allograft is listed for peripheral nerve reconstruction by the FDA. All marketed nerve grafts are able to demonstrate sufficient nerve regeneration over small distances not exceeding 3.0 cm. A key question in the field is whether nerve reconstruction on large defect lengths extending 4.0 cm or more is possible. This review gives a summary of current clinical and experimental approaches in peripheral nerve surgery using artificial and non-artificial nerve grafts in short and long distance nerve defects. Strategies to extend nerve graft lengths for long nerve defects, such as enhancing axonal regeneration, include the additional application of Schwann cells, mesenchymal stem cells or supporting co-factors like growth factors on defect sizes between 4.0 and 8.0 cm.

Keywords FDA · Cell transplantation · Artificial graft · Autograft · Allograft

Nerventransplantate für periphere Nervenverletzungen ausgedehnter Defektgrößen

Zusammenfassung Der Goldstandard in der Versorgung von peripheren Nervendefekten ist nach wie vor die autologe Transplantation. Sollte eine Versorgung des Defekts mittels eines autologen Transplantats nicht möglich sein, so gibt es die Möglichkeit, auf von der U.S. Food and Drug Administration (FDA) zugelassene künstliche Nervenimplantate zurückzugreifen. Diese sind jedoch nur für periphere Nervendefekte <3,0 cm erprobt und zugelassen, für Defekte, welche diese 3,0 cm übersteigen, gibt es derzeit keine zugelassenen Alternativen. Für durch Tumorinfiltration oder Trauma entstehende Defekte werden diese aber dringend benötigt. Der Reviewartikel gibt einen Überblick über aktuelle Forschungsansätze mit dem Ziel der Transplantatversorgung langstreckiger Nervendefekte und zeigt die Notwendigkeit neuer, innovativer Forschungsansätze auch im Bereich der autologen Zelltransplantation.

Schlüsselwörter FDA · Zelltransplantation · Kunsttransplantat · Autotransplantat · Allogenes Transplantat

Abbreviations

CMAP Compound action potentials
CSPGs Chondroitin sulfate proteoglycans
EM Electron microscopy
ENT Ear, nose and throat
FDA US Food and Drug Administration
FGF Fibroblast growth factor
MHC Major histocompatibility complex
Peripheral nerve damage is a severe and critical problem in all disciplines of surgery. With an overall incidence of 17.4% of iatrogenic acquired nerve lesions, this appears to be an underestimated major problem in patient treatment [1]. Several cases have been reported where a peripheral nerve was mistakenly used as a muscle tendon graft [2, 3] or nerve fibers have been damaged during anesthetic interventions [4–6]. The vast majority of peripheral nerve defects are caused by severe trauma or tumor infiltration. Noble et al. revealed that severe trauma leads to peripheral nerve injury with a prevalence of 2.8% in level 1 trauma patients [7].

Whether the nerve defect is caused iatrogenically or traumatically there is no difference in the surgical approach for nerve reconstruction. The current gold standard in nerve repair surgery is the tension free approach for nerve reconstruction. The current gold standard in nerve repair surgery is the tension free approach for nerve reconstruction. The current gold standard in nerve repair surgery is the tension free approach for nerve reconstruction. The current gold standard in nerve repair surgery is the tension free approach for nerve reconstruction. The current gold standard in nerve repair surgery is the tension free approach for nerve reconstruction. Noble et al. revealed that severe trauma leads to peripheral nerve injury with a prevalence of 2.8% in level 1 trauma patients [7].

Artificial nerve grafts can be used as an alternative in cases of multiple nerve lesions where subsequent treatment with autografts is not possible due to limitation of donor tissue [11]. A variety of artificial nerve grafts is commercially available and approved by the FDA (US Food and Drug Administration) [12]. The data of the FDA revealed that collagen, chitosan and poly (DL-lactide-ε-caprolactone) are the most frequently used and approved materials (Table 1). Table 1 summarize all marketed and FDA-approved artificial nerve grafts for the surgical reconstruction of peripheral nerve tissue.

The first collagen based peripheral nerve implants were approved for surgical intervention by the FDA in the early 2000s. Nearly simultaneously Neurogen® (Integra Lifescience Corporation, Plainsboro, NJ, USA) and Neuroflex® (Collagen Matrix Inc, Oakland, NJ, USA) have been introduced to the market. Neurogen® is a collagen based nerve tube demonstrating a satisfying recovery rate of 43% of level 1 trauma treated patients with peripheral nerve defects pending between 2.5–20.0 mm in length [13]. Neuoflex® is a collagen based nerve tube distributed by Stryker Corporation (Stryker Corporation, Kalamazoo, MI, USA). No clinical data is available after intensive literature research. Importantly, the collagen based materials have a significant low antigenicity and immunogenicity in vivo what makes them to a favorable material for in vivo applications [14].

Reaxon plus® (Medovent GmbH, Mainz, Germany) represents an approved conduit constructed out of the natural biomaterial chitosan. Chitosan was successfully used in rodent animal experiments for nerve regeneration over distances of up to 15.0 mm [15]. In this study nerve regeneration using chitosan nerve grafts was as effective as autologous nerve transplantation. Subsequent studies revealed that chitosan nerve grafts are able to reduce post-traumatic formation of neuroma and epineural fibrosis [16]. Unfortunately, chitosan was also reported to induce a foreign body reaction during degradation in vivo [17].

Neurotube® (Neuroregen L.C.C, Bel Air, MD, USA) and Neurolac® (Polyganics BV, Rozenburglaan, Netherlands) are nerve cuffs manufactured out of poly(DL-lactide-ε-caprolactone) and are approved for surgical reconstruction of nerve defects up to 3.0 cm in length. Neurotube® demonstrated successful facial nerve regeneration in several cases on defect sizes between 1.0 and 3.0 cm [18]. No signs of tissue retraction or inflammation processes occurred during application in human facial nerve repair. However, Duncan et al. report a case concerning the extrusion of a Neurotube® implant associated with inflammation processes [19]. Neurolac® is a competitive product to Neurotube® and one report suggests improved regeneration compared to autologous nerve grafts on a 1.0 cm peripheral nerve defect in rodents [20]. Supporting the results from den Dunnen et al. [19] a case series from Brazil indicates that the use of Neurolac® is a safe and successful procedure for peripheral nerve surgery [21].

AxoGen Avance® (AxoGen, Alachua, FL, USA) is the only FDA approved human nerve allograft. In several studies in animal models the efficiency of nerve regeneration through decellularized allograft was demonstrated, but was still inferior to isografts [22]. Clinical trials revealed that 87% of 132 nerve injuries treated with Axogen Avance® (A xoGen, Alachua, FL, USA) regained sensory and/or motor functions for treated peripheral nerve defect sizes between 5.0 and 50.0 mm [23]. Just recently Rinker et al. analyzed the results of the Ranger I study in regard to peripheral nerve defects on small diameter nerve defects on the hand [24]. Accordingly to the results of Brooks et al. [23] nerve regeneration with regained sensory function (S3+ or higher) was observable in 86% of the included cases.

All marketed and FDA approved nerve grafts demonstrate satisfying recovery on defect length from up to 3.0 cm with a minimal amount of side effects or regeneration failure. Despite these high number of FDA approved and commercially available artificial nerve grafts for reconstruction of peripheral nerve defects, no implant is approved and available for defect sizes extending 3.0 cm or longer in length. Nerve defects extending these 3.0 cm are usually considered to be critical [25]. Good clinical and non-clinical data is available for short nerve defects not extending 3.0 cm [13–21]. Recently Kaplan et al. criticized that only little clinical data is available for long gaped peripheral nerve defects and that rodent animals might not
Table 1  FDA-approved nerve tubes for peripheral nerve repair. (Modified and supplemented from FDA Medical Device Database [104])

| Name                        | Product name     | Company                        | Date of approval | K510   | Available Length (cm) | Material                                |
|-----------------------------|------------------|--------------------------------|------------------|--------|-----------------------|-----------------------------------------|
| Neuragen 3D                 | NeuraGen®        | Integra Lifescience Corporation, Plainsboro, NJ, USA | Apr 24, 2014     | K130557 | 3.0                   | Collagen                                |
| Neuron X Nerve Guide        | NeuroGen®        | Integra Lifescience Corporation, Plainsboro, NJ, USA | Jun 22, 2001     | K011168 | 3.0                   | Collagen                                |
| Flexible collagen nerve     | NeuroFlex®       | Collagen Matrix Inc., Oakland, NJ, USA | Apr 03, 2014     | K131541 | 2.5                   | Collagen                                |
| Collagen nerve cuff         | NeuroGen®        | Collagen Matrix Inc., Oakland, NJ, USA | Sep 21, 2001     | K012814 | n.a                   | Collagen                                |
| Reaxon Plus®                | Reaxon Plus®     | Medovent GmbH, Mainz, Germany  | Dec 02, 2015     | K143711 | 1.0                   | Chitosan                                |
| NeutroTube®                 | NeutroTube®      | Neuroregen L.C.C, Bel Air, MD, USA | Mar 22, 1999     | K093007 | 3.0                   | Poly(DL-lactide-ε-caprolactone)         |
| Neurorac® Nerve Guide       | Neurorac®        | Polyganics BV, Rozenburglaan, Netherlands | Oct 20, 2011     | K112267 | 2.0                   | Poly(DL-lactide-ε-caprolactone)         |
| Neurorac® Nerve Guide       | Neurorac®        | Polyganics BV, Rozenburglaan, Netherlands | May 04, 2005     | K050573 | 2.0                   | Poly(DL-lactide-ε-caprolactone)         |
| Neurorac® Nerve Guide Models| Neurorac®        | Polyganics BV, Rozenburglaan, Netherlands | Oct 10, 2003     | K032115 | 2.0                   | Poly(DL-lactide-ε-caprolactone)         |
| AxoGen Avance®              | AxoGen Avance®   | AxoGen, Alachua, FL, USA       | –                | –      | 5.0                   | Human nerve allograft                   |

be a suitable animal model for translational research in peripheral nerve surgery [25]. Sufficient data concerning larger gap sizes is rare and the vast majority of scientific approaches does not lead to the expected results. Nevertheless surgical approaches for long gap nerve defects are needed during daily medical practice. Especially extended and multiple injuries of e.g. plexus nerves by trauma or long length tumor infiltration of peripheral nerve tissue are challenging in reconstruction. These review gives a brief overview about current approaches in peripheral nerve surgery for critical gap sizes between 4.0 and 8.0 cm in small and large animal models using acellular nerve grafts or pre-seeded conduits.

Material and methods

Including criteria

Only scientific work in regard to peripheral nerve regeneration/reconstruction was included. Main criteria was a surgical nerve reconstruction in small/large animal models with artificial/non-artificial nerve grafts on nerve defect sizes ≥4.0 cm.

Matches

In all, 30 original articles met the inclusion criteria of nerve reconstruction on nerve defects ≥4.0 cm. Four records were excluded after identified as duplicates. Two article were removed due to incomparable methods.

Literature search

A literature search was performed via PubMed and Google Scholar. A key word search was performed using the following: “long gap nerve defects”, “extended nerve defects”, “reconstruction of extended nerve defects”, “critical sized nerve defects”, “nerve defects in large animal models”.

Current experimental approaches in peripheral nerve reconstruction

Small animal models

Small animal models are widely used in experimental in vivo investigation in the field of peripheral nerve surgery [22, 26–28]. High availability with moderate holding costs makes them a competitive and indispensible model for efficient and high throughput surgical testing experiments [29]. The sciatic nerves are easily accessible via a dorsal operation route. Postsurgical nerve regeneration can be evaluated in vivo either by electrophysiology, nerve pinch test or walking track analysis [30, 31]. Literature shows that the small animal models are also suitable for nerve surgery in settings with nerve defects extending 4.0 cm in length [32–40]. A disadvantage of the rodent model is that the
Table 2: Small animal models in peripheral nerve surgery

| Defect size (cm) | Nerve | Animal | Implant | Time | Outcome | Quotation |
|-----------------|-------|--------|---------|------|---------|-----------|
| **Small animal models in nerve surgery without cell transplantation** |
| 1 4.0 | Tibial nerve | Rat | Chondroitinase ABC processed nerve | 3 M | Higher numbers of regenerated axons compared to control | Neubauer et al. [32] |
| 2 6.0 | Sciatic nerve | Rat | Allograft vs. autograft | 20 W | Superior regeneration in allograft group compared to control | Saheb-al-Zamani et al. [33] |
| 3 3.0, 5.0, 7.0 | Saphenous nerve | Rabbit | Autograft | 15 M | Decreasing regeneration with increasing defects size | Koller et al. [34] |
| 4 5.0 | Sciatic nerve | Rabbit | Muscle grafts | 4 M | Light regeneration in muscle grafts | Migiliche et al. [35] |
| 5 10.0 | Sciatic nerve | Rabbit | Muscle grafts | 2 M | No regeneration | Hems et al. [36] |
| **Small animal models in nerve surgery with cell transplantation** |
| 6 4.0 | Tibial nerve | Rabbit | Autologous vein with and without SC, Autograft as a control | 2 M | Axonal regeneration in Isograft group and Vessel filled with Schwann cells | Zhang et al. [37] |
| 7 1.0–6.0 | Peroneal nerve | Rabbit | Vein | – | Regeneration on 3.0 cm. Poor outcome on long distances | Strauch et al. [39] |
| 8 6.0 | Peroneal nerve | Rabbit | Vein | 4 M | Regeneration on full distance | Strauch et al. [38] |
| 9 4.0 | Ulnar nerve | Rat | ε-caprolactone-co-trimethylene carbonate filled with Schwann cells | 12 M | No regeneration, extended formation of neuroma | Sinis et al. [40] |

M month, W week

dynamics of peripheral nerve regeneration may be different than in large animal models including humans, due to issues of scale [25, 41]. Table 2 gives a brief overview of current approaches in peripheral nerve surgery in small rodent animal models with or without cell transplantation and the addition of co-factors (Table 2).

**Acellular nerve grafting**

In cases were an alternative to the standard nerve end-to-end suture is desperately needed it can be defaulted to autologous nerve grafts or peripheral allografts as previously mentioned [11]. An acellular allograft or an artificial nerve graft appears as a widely investigated and suitable alternative. Especially isografts and acellular allograft have been extensively investigated in recent decades [42–44].

A recent study concerning nerve grafting with the previously mentioned acellular allograft was carried out on a 4.0 cm sciatic nerve defect in Fischer F344 rats with thermally decellularized allografts pretreated with chondroitinase ABC to breakdown axon inhibitory chondroitin sulfate proteoglycans (CSPGs) [32]. The authors report that nerve grafts pretreated with chondroitinase ABC shows a higher number of regenerated myelinated axons distal of the grafts suture compared to controls. Functionally they observed a higher number of positive nerve pinch tests and a reduction of retrograde axon growth in pre-treated allografts indicating that chondroitinase ABC can support nerve regeneration over long nerve defect distances.

Whether the limited regeneration in long nerve grafts is caused by high doses of chondroitin sulfate proteoglycan and other scar related axon inhibitory elements or increasing number of senescent Schwann cells is not known. Saheb-Al-Zamani et al. investigated nerve regeneration through 2.0, 4.0 and 6.0 cm acellular nerve allografts [33]. Results demonstrate high expression of senescence markers (p16INK4A and β-galactosidase) in all grafts. Electron microscopy (EM) revealed a rising number of chromatin clumped cell nuclei with central involution in Schwann cells on acellular allografts >4.0 cm which is typical for cell aging. However, reorganization of chromatin in cell nuclei was not verifiable in short nerve grafts of 2.0 cm allograft and isografts respectively. Independent of this, nerve regeneration in autografts was superior to acellular allografts due to significantly higher numbers of myelinated fibers in distal parts of the nerve segments.

Another study investigated nerve regeneration using an autologous nerve graft on defect distances from 3.0, 5.0 and 7.0 cm in length in rabbit [34]. Maximum tetanic tension and number of myelinated axons deteriorate with increasing autograft length over a maximum 15-month observation time. Koller et al. reported that this result may indicate that nerve regeneration over a distance up to 7.0 cm is possible and the poor outcome regarding tetanic tension and re-myelination is explained by inferior vascularization in long length peripheral nerve grafts.
As an alternative to allo- and autografts, acellular muscle autografts have been investigated. The approach was first used in early the 1980s and 1990s [45–47]. Milgliche et al. carried out a study using acellular muscle autografts on a 5.0 cm sciatic nerve defect in Japanese white rabbits [35]. After 4 months following implantation, compound action potentials (CMAP) and EM recordings were performed. Results indicate regeneration within the acellular muscle graft throughout the entire defect length with decreasing number of myelinated axons dependent upon graft length. CMAP shows light reinnervation on target muscle in each graft.

Hems et al. [36] performed a similar experiment in white New Zealand rabbits. Coapting a 5.0 and 10.0 cm sciatic nerve defect using cold freeze-dried muscle grafts compared to an autologous nerve graft. Light microscopy revealed inferior recovery in muscle grafts compared to controls. Nerve regeneration deteriorates after 2.0 cm and graft tissue was replaced by fat and connective tissue.

Data on long gapped peripheral nerve defects in small animals are limited possibly due to the issue of scale. However, small animal studies revealed that peripheral nerve regeneration through autologous donor nerves is nearly possible without side effects and that regeneration through artificial nerve grafts constructed from various materials is possible. Regeneration in allografts was reported to be less satisfactory than expected [32, 33]. Given these caveats in small animal models they have certainly provided valuable information that has advanced the field.

**Grafting with autologous donor cells**

Schwann cells play a crucial role not only for myelination of peripheral nerve fibers, but for providing trophic support and structural guidance for axonal regeneration [48]. After nerve damage and during Wallerian degeneration when axons are degenerating, the Schwann cells disassociate from the axons and they begin to divide [49]. These changes are within the endoneurial tubes or bands of Büngner. It is well established that Schwann cells not only form myelin for the electric insulation of peripheral nerves, but play a major role during the regeneration process of the peripheral nervous system by producing trophic factors and structural guidance for axonal growth [49, 50]. Several studies have investigated whether autologous Schwann cells can support peripheral nerve regeneration in artificial and non-artificial nerve grafts [51–55].

Experiments have been carried out to test Schwann cells on defect sizes <3 cm [53–56]. A 4.0 cm autologous monochanneled vein graft pre-seeded with 1 × 10^6 Schwann cells was successfully used on large nerve defects up to 6.0 cm, Sinis et al. [40] demonstrated negative results after treating a 4.0 cm nerve defect in rat, with a monochanneled ε-caprolactone-co-trimethylene carbonate graft which was seeded with autologous Schwann cells. Autologous nerve graft controls demonstrate effective nerve regeneration as demonstrated by electrophysiology and immunohistology. Unfortunately, the newly developed ε-caprolactone-co-trimethylene artificial nerve graft showed extended formation of neuroma in 13 out of 16 animals.

**Large animal models**

Allograft and autografts in several nerve defect injury models in small animals have indicated that regeneration is possible on critical nerve defects. As previously mentioned Koller et al., Neubauer et al. and Saheb-Al-Zamani et al. were able to demonstrate that nerve regeneration in nerve defects up to a maximal length of 7.0 cm in small animals (rabbit, rat) is realistic [32–34].

In order to achieve results that are applicable to humans, a translational large animal model for peripheral nerve surgery is highly important. There is no standard large animal model for nerve repair studies, but a number of species are used in other disciplines. The ovine animal model is established as a standard
Table 3  Large animal models in peripheral nerve surgery

| Defect size (cm) | Nerve      | Model  | Implant                                      | Time  | Result                                                                 | Author             |
|-----------------|------------|--------|----------------------------------------------|-------|------------------------------------------------------------------------|--------------------|
|                 |            |        |                                              |       |                                                                        |                    |
| 1               | 8.0        | Mesian nerve | Sheep | Autolog vs. allograft | 6 and 10 M | No regeneration in allografts. Good results in autografts | Strasberg et al. [65] |
| 2               | 8.0        | Ulnar nerve | Swine | Autograft vs. allograft | 6 and 10 M | Autograft significant superior to allograft | Atchabahian et al. [67] |
| 3               | 7.0        | Median nerve | Sheep | Autograft | 6 and 9 M | Slightly decreased results in electrophysiology compared to untreated controls | Forden et al. [66] |
| 4               | 5.0        | Sciatic nerve | Cat  | Freeze-dried alginate gel covered by polyglycolic acid mesh | 7 M | Recovery through alginate gel is possible | Suzuki et al. [68] |
| 5               | 5.0        | Sciatic nerve | Cat  | Freeze-dried alginate gel covered by polyglycolic acid mesh | 10 M | Good regeneration without tubular structure | Sufan et al. [71] |
| 6               | 8.0        | Peroneal nerve | Dog  | PGA-collagen-laminin | 12 M | Regeneration throughout the conduit with some differences in histological appearance | Matsumoto et al. [72] |
| 7               | 2.0, 5.0   | Ulnar nerve | Primate | Maxon® collagen graft | 14 M | Maxon® is superior compared to controls on defects sizes <2.0 | Mackinson et al. [81] |
| 8               | 6.0        | Tibial nerve | Sheep | Vein filled with spider silk vs. autograft | 10 M | Full functional recovery | Radtke et al. [64] |

Large animal models in nerve surgery with immunosuppression or cell transplantation/co-factors

| Defect size (cm) | Nerve      | Model  | Implant                                      | Time  | Result                                                                 | Author             |
|-----------------|------------|--------|----------------------------------------------|-------|------------------------------------------------------------------------|--------------------|
|                 |            |        |                                              |       |                                                                        |                    |
| 9               | 4.0        | Ulnar nerve | Primate | Allografts with MSC | 6 M | Good recovery but inferior to isografts and Schwann cell seeded nerve grafts | Hu et al. [74] |
| 10              | 8.0        | Peroneal nerve | Sheep | Autograft, allograft + cyclosporine A | 35 and 47 d | Major side effects due immunosuppression | Matsuyama et al. [99] |
| 11              | 4.0        | Ulnar nerve | Primate | Autograft, allograft + FK506 | 8 M | Comparable results of autograft and allograft + Fk506 | Auba et al. [75] |
| 12              | 5.0        | Ulnar nerve | Primate | Autograft, allograft + anti-CD40 ligand | 4 and 6 M | Anti-CD40 ligand monoclonal antibody can improve regeneration | Brenner et al. [73] |
| 13              | 5.0        | Ulnar nerve | Swine  | Allografts + MHC Schwann cells + controls without cells | 20 W | Good results regarding cold preservation of allografts | Brenner et al. [101] |
| 14              | 5.0        | Peroneal nerve | Dog  | Allograft, autograft + bFGF | 1 and 3 M | FGF can improve regeneration, 5.0 are possible without immunosuppression | Ide et al. [163] |
| 15              | 8.0        | Ulnar nerve | Swine  | Autograft, allograft + FK506 | 24 W | FK506 improve regeneration, major side effects due to immunosuppression | Jensen et al. [102] |

M month, W week, d day

surgery model regarding orthopedic questions to investigate treatment options in arthrosis, osteoarthritis or damage of cruciate ligaments [57–59]. Porcine animals are predominantly used in trauma and intensive care research [60–62] and feline models are used as ear, nose and throat (ENT) surgical standard models [63]. Artificial nerve conduits have been used successfully in different ovine animal models [64–66], yet there is no standard animal model on large peripheral nerve surgery. Table 3 gives an overview of study designs in peripheral nerve surgery using large animal models.

In 1996 Strasberg et al. [65] used an ovine animal model to investigate an 8.0 cm peripheral nerve defect on median nerves surgically treated with either autologous nerve graft, nerve allograft, cold-preserved autograft or cold preserved allografts, thus introducing the ovine animal as a large animal model for peripheral nerve surgery. Analyses were performed after 6 and 10 months post-surgery. They concluded that both fresh autograft and cold-preserved autograft demonstrated nerve regeneration across the 8.0 cm nerve gap. Unfortunately, fresh allograft and cold preserved allografts demonstrated insufficient axonal regeneration.

Subsequently a study in the porcine animal model was performed with slightly modified parameters. In 12 adult swine an 8.0 cm bilateral ulnar nerve defect was induced and treated with an autologous nerve graft or a nerve allograft [67]. After 6 and 10 months
nerves were harvested and histomorphometry revealed nerve regeneration and remyelination in the autologous nerve transplant group. As previously shown in the ovine animal model [65] the regeneration of the allograft treated group remained unsatisfactory.

About 15 years later experiments in sheep were performed and reintroduced the sheep as a large animal model for nerve repair surgery [66]. Results from a median nerve defect in the sheep with a defect length of 5.0 cm coapted with a 7.0 cm autologous radial nerve graft was explored. After 6 and 9 months of surgery animals were euthanized and nerve grafts were analyzed regarding axonal regeneration. Electrophysiology revealed an insignificant difference between autograft and control. Results demonstrated regeneration throughout the entire graft length. Morphometric analyses showed axons with significantly smaller diameter in autologous nerve graft after 6 and 9 months compared to control, which is characteristic of regenerated axons. Extrafascicular and endoneurial tissue were distinct. Forden et al. were able to show that the median nerve in sheep was an adequate model for nerve repair surgery. Thus, they were able to reproduce the results of Strasberg et al. [63] with an improved surgical and methodological approach.

Another study investigating freeze dried alginate gel on 5.0 cm sciatic nerve defects in cat [68]. Alginate was previously used in chronic wound healing and wound dressing [69, 70]. After 3 and 13 weeks compound muscle action potentials showed ongoing regeneration in the implant group with increasing latency and amplitudes after 13 weeks. Histomorphological analysis using electron microscopy (EM) demonstrated axon regeneration throughout the conduit 7 months following surgery. As already shown in the studies by Forden et al. [66] myelinated axons appeared with a significantly smaller diameter compared to controls.

In order to improve alginate as a material in peripheral nerve surgery, the experiments were repeated by Sufan et al. on a 5.0 cm sciatic defect model in feline animals two years later with a completely modified implant design [71]. A tubulated implant constructed from freeze dried alginate and polyglycolic acid (PGA) was compared to a non-tubulated alginate only graft. EM revealed regeneration in both graft groups independent of the tubulated and non-tubulated graft 10 months after surgery. As expected from prior studies from Suzuki et al. [68] and Forden et al. [66], axons appeared myelinated and smaller in diameter than in normal nerve tissue. Suzuki et al. were able to demonstrate that regeneration within the two different nerve grafts is comparable.

Following an entirely different approach Matsumoto et al. performed an experiment in 16 adult canine animals on an 8.0 cm peroneal nerve defect repaired with a polyglycolic based conduit filled with laminin coated collagen fibers [72]. The peroneal nerve was harvested 12 months post-surgery. Monthly recorded compound muscle action potentials (CMAPs) demonstrated incomplete regeneration throughout the 8.0 cm artificial nerve graft. EM showed that regeneration is still ongoing though decreasing axon diameter and number of myelinated axons. Immunohistochemistry could demonstrate growing neurofilament positive nerve fibers in the distal nerve stump. Matsumoto et al. were able to develop a suitable PGA-collagen implant for surgical intervention on large peripheral nerve defects.

Several experiments in nerve surgery have been carried out in non-human primates [73–75]. Primates are regarded as an important translational animal model in medicine for some situations [76, 77]. Nonetheless the cost and ethical concerns limit their use [78–80]. Mackinson et al. compared a synthetic glycolide trimethylene carbonate nerve graft with a collagen based conduit in a 2.0 cm and 5.0 cm ulnar/radial nerve defect in non-human primates [81]. The 14 month post-surgery results demonstrate a complete and excellent regeneration through the 2.0 cm grafts. Regeneration over a 5.0 cm nerve gap was significantly better in glycolide trimethylene carbonate conduits than in collagen based grafts but still poor in comparison to the 2.0 cm grafts.

Radtke et al. used a nerve implant constructed out of spider silk gained from the species Nephila inside of a decellularized vessel for reconstruction of a 6.0 cm tibial nerve defect in ovine animals [64]. The spider silk nerve implant shows good results in electrophysiology and histological examination 10 months post-surgery. Results indicate that nerve regeneration through the spider silk nerve implant is at least as effective as autologous nerve grafts. The spider silk conduit was designed and prior to application in large animal model extensively tested in vitro and in small animal models in vivo [82–86]. Especially results of the current in vitro investigation of the spider silk based nerve implant emphasize that the implant might be suitable for nerve reconstruction on defect sides extending 6.0 cm in length [82]. Outcome of previous in vitro study are currently being reevaluated in the ovine animal model [82]. Results of these in vivo investigation are pending. Although spider silk is a natural material it appears to be suitable for different surgical approaches due to its mechanical and thermal properties [87–93]. Radtke et al. briefly reviewed the use of silk in relation to peripheral nerve reconstruction and regeneration and discussed future material optimization and translation to daily medical practice [94].

Grafting with cell transplantation on long gaped nerve defects

Mesenchymal stem cells (MSCs) play a major role in proliferation and differentiation during regenerating processes in tissue e.g. fat, bone and cartilage. An
interesting property of MSCs with regard to nerve regeneration is the interaction they have with the innate and adaptive immune system as well as the down regulation of proinflammatory cytokines in damaged tissue [95].

Jun Hu et al. used this approach to investigate an allograft on a 4.0 cm ulnar nerve defect in non-human primates [74]. Allograft pre-seeded with MSCs were compared to Schwann cell seeded allograft, acellular autografts and acellular controls. After 6 months, the results indicated that regeneration in allografts with MSCs are better than in acellular controls, but still inferior to grafts pre-seeded with Schwann cells and isografts.

Grafting with immunosuppression

Immunosuppression is needed to prevent foreign body reactions and rejections of implants [96]. Allografts have been reported to precipitate immune reactions resulting in implant rejection [97]. Cyclosporine A usually used after organ transplantation [98] was used to prevent allograft rejection in ovine animals on a 5.0 cm median nerve defect grafted with an 8.0 cm allograft [99]. Immunosuppression led to severe bacterial infections resulting in controlled experimental truncation. However, the results indicated that immunosuppression can prevent tissue rejection of allografts.

On the other hand, FK506 (tacrolimus) was able to demonstrate enhanced nerve regeneration in allografts in small rodents [100]. Auba et al. used a nonhuman primate model with immunosuppression [75]. A 4.0 cm nerve defect in nonhuman primate ulnar nerve was inducted and coapted with either allograft under immunosuppression (2 months only) with FK506 or isograft. Apart from slightly elevated nerve conduction velocities in the autologous control no significant difference was observed in the histological analysis 8 months after surgery. The investigators reported that this could indicate tissue rejection within the allograft.

Instead of using a systemic immunosuppression to prevent allograft rejection Brenner et al. used anti-CD 40 ligand monoclonal antibody on a 5.0 cm ulnar nerve defect in non-human primates [73]. To investigate the full influence of anti-CD 40 ligand monoclonal antibody a skin allograft was transplanted additionally to the nerve allograft in one group. Results demonstrated that anti-CD 40 ligand monoclonal antibody is able to avoid foreign body reactions that lead to tissue rejection ensuring equal regeneration compared to autografts. Skin grafts were rejected and indicate partial rejection of nerve allografts supposed to be caused by overwhelming foreign body reactions. A subsequent approach by Brenner et al. was to use pre-seeded allograft with MHC matched Schwann cells to downregulate foreign body reactions in porcine animals with and without pre-operative ultraviolet-B donor alloantigen injections [101]. Therefore a 5.0 cm ulnar nerve allograft model was designed. Allografts + MHC-Schwann cells resulted in excellent nerve regeneration compared to controls. Influence of UV-B donor alloantigen injections is not fully understood.

In 2005 Jensen et al. performed an experiment in 8 outbred swine [102]. An 8.0 cm ulnar nerve defects was reconstructed with an autologous nerve graft and allografts. Six operated animals received an FK506 injection every 14 days to maintain immunosuppression. Three FK506 treated animals deceased before experimental endpoints suffering pulmonary abscess, infarcted bowel or cardiac arrest. Results demonstrate a comparable regeneration in FK506 allografts compared to untreated autografts. Autografts from animals treated with FK506 showed a slight improved regeneration compared to autologous controls.

Grafting without immunosuppression

Brenner et al. [73, 101], Matsuyama et al. [99] and several other investigators demonstrated that allografting without immunosuppression leads to tissue rejection. Ide et al. tested an acellular allograft in combination with fibroblast growth factor (FGF) on a 5.0 cm peroneal nerve defect in a canine animal model [103]. They report that nerve regeneration throughout the allograft is possible without immunosuppression. However, the regeneration is less than that obtained from autografts. Clearly the use of immunosuppression is an important issue for use of autografts and research in this area is critical for non-autologous biosynthetic graft construction and use in clinical studies for nerve repair.

Conclusion

Translation to clinical practice

Ongoing developments in peripheral nerve surgery are auspicious. Allografts are nearly a perfect alternative to the current gold standard technique, especially because immunosuppression is not indicated anymore to avoid a foreign body reaction. Nerve grafting with cell suspensions e.g. with Schwann cells shows promising results on small defect sizes in animals but is limited on translation to human organism by highly regulated local laws for transplantation of human stem cells. Muscle grafts and mononeuronal nerve grafts are not appropriate for reconstruction of long gaped peripheral nerve defects. Nerve reconstruction with biomaterials like spider silk are as good as the autologous gold standard. Research is still ongoing and transfer to the human organism is pending.
Research approaches

A literature search demonstrated that scientific approaches and animal models in peripheral nerve surgery are extremely versatile with the result of limited and impeded possibilities of comparison. Scientists in the field of peripheral nerve surgery should focus on comparable approaches regarding animal models and methods to produce comparable and competitive results. Nevertheless most reviewed approaches are promising regarding future clinical translation. Especially the transplantation of autologous donor cells and factors within artificial and non-artificial nerve grafts might be advantageous in future settings.

Effect on daily medical practice

The autologous nerve graft is still and with good reason the gold standard for reconstruction of peripheral nerve tissue. Nevertheless autologous donor material is highly limited in number and often mismatch the nerve defects of the reconstruction side. Especially multiple long gaped plexus injuries are challenging during reconstruction. Furthermore the donor side morbidity after autograft harvest can lead to post-op-erative complications e. g. with neuroma formation, permanent sensitivity loss and adherent scars. Obviously autologous donor harvest is limited. In those surgical settings with limited availability of donor tissue the use of artificial nerve grafts should be recom-mended for peripheral nerve defects <3.0 cm. Both artificial nerve graft e. g. NeuroGen®, Neurotube®, Neurolac® and nerve allografts e. g. AxxoGen® Avance can be recommended as alternative approaches for nerve reconstruction after literature analysis. Tran-slational and alternative approaches for the reconstruction of long gaped defect sides are desperately needed. Especially the cell free approaches including allografts or spider silk nerve implants could be a contemporary and sufficient transfer technology beside neurotization until cell based procedures are safe and a stat-u-tory basis is set.

Funding This work was funded by the Volkswagen Foundation.

Funding Open access funding provided by Medical University of Vienna.

Conflict of interest T. Kornfeld, P.M. Vogt, and C. Radtke declare that they have no competing interests.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Kretschmer T, Antoniadis G, Braun V, Rath SA, Richter HP. Evaluation of iatrogenic lesions in 722 surgically treated cases of peripheral nerve trauma. J Neurosurg. 2001;94(6):905–12.
2. McGeorge D, Sturzenegger M, Buechler U. Tibial nerve mistakenly used as a tendon graft. Reports of three cases. Bone Joint J. 1992;74-B(3):365–6.
3. Weber RV, Mackinnon SE. Median nerve mistakenly for mal-maris longus tendon: restoration of function with sensory nerve transfers. Hand (NY). 2007;2(1):1–4.
4. Renton T, Adey-Viscuso D, Meechan JG, Yilmaz Z. Trigem-inal nerve injuries in relation to the local anaesthesia in mandibular injections. Br Dent J. 2010;209(9):E15–E15.
5. Sawyer RJ, Richmond MN, Hickey JD, Jarratt JA. Peripheral nerve injuries associated with anaesthesia. Anaesthesia. 2000;55(10):980–991.
6. Jung Kim H, Hyan Park S. Sciatic nerve injection injury. J Int Med Res. 2014;42(4):887–97.
7. Noble J, Munro CA, Prasad VS, Midha R. Analysis of upper and lower extremity peripheral nerve injuries in a popula-tion of patients with multiple injuries. J Trauma. 1998;45(1):116–22.
8. Seddon HJ. Nerve grafting. Ann R Coll Surg Engl. 1963;32:269–80.
9. Siemionow M, Brzezicki G. Chapter 8: current techniques and concepts in peripheral nerve repair. Int Rev Neurobiol. 2009;87:141–72.
10. Ray WZ, Mackinnon SE. Management of nerve gaps: autografts, allografts, nerve transfers, and end-to-side neurorrhaphy. Exp Neurol. 2010;223(1):77–85.
11. Arslantunali D, Dursun T, Yucel D, Hasirci N, Hasirci V. Periphe-ral nerve conduits: technology update. Med Devices (Auck). 2014;7:405–24.
12. Kehoe S, Zhang XE, Boyd D, FDA approved guidance con-duits and wraps for peripheral nerve injury: a review of materials and efficacy. Injury. 2012;43(5):553–72.
13. Wangensteen KJ, Kallainen LK. Collagen tube conduits in peripheral nerve repair: a retrospective analysis. Hand (N Y). 2010;5(3):273–7.
14. Lynn AK, Yannas IV, Bonfield W. Antigenicity and immuno-genicity of collagen. J Biomed Mater Res Part B Appl Biomater. 2004;71(2):343–54.
15. Haastert-Talini K, Geuna S, Dahlin LB, Meyer C, Stenborg L, Freier T, et al. Chitosan tubes of varying degrees of acety-lation for bridging peripheral nerve defects. Biomaterials. 2013;34(38):9886–904.
16. Marcel W, Larysz-Brysz M, Kucharska M, Niekraszewicz A, Slusarczyk W, Kutolska K, et al. Reduction of post-traumatic neuroma and epineural scar formation in rat sciatic nerve repair: application of microcrystalline chitosan. Microsurgery. 2011;31(8):642–9.
17. Duda S, Dreyer L, Behrens P, Wiesecke S, Chakradeo T, Glasmacher B, et al. Outer electrop spun polycaprolactone shell induces massive foreign body reaction and impairs axonal regeneration through 3D multichannel chitosan nerve conduits. Biomed Res Int. 2014;2014:635269.
18. Navissano M, Malan F, Carnino R, Battiston B. Neurotube® for facial nerve repair. Microsurgery. 2005;25(4):268–272.
19. Duncan SE, Kinokuni R, Rizzo M, Kang W. Extrusion of a Neurotube: a case report. Ochsner J. 2015;15(2):191–2.
20. den Dunnen WF, van der Lei B, Schakenraad JM, Stokroos I, Blaauw E, Bartels H, et al. Poly(DL-lactide-ε-caprolactone) nerve guides perform better than autologous nerve grafts. Microsurgery. 1996;17(7):348–57.
21. Costa Serrão de Araújo G, Couto Neto B, Harley Santos Botelho R, Carpi Malta M. Clinical evaluation after peripheral nerve repair with caprolactone neurotube. Hand. 2016; https://doi.org/10.1177/1558944716643277.

22. Whitlock EL, Tuffaha SH, Luciano JP, Yan Y, Hunter DA, Magill CK, et al. Processed allografts and type I collagen conduits for repair of peripheral nerve gaps. Muscle Nerve. 2009;39(6):787–99.

23. Brooks DN, Weber RV, Chao JD, Rinker BD, Zoldos J, Robichaux MR, et al. Processed allografts for peripheral nerve reconstruction: a multicenter study of utilization and outcomes in sensory, mixed, and motor nerve reconstructions. Microsurgery. 2012;32(1):1–14.

24. Rinker B, Zoldos J, Weber RV, Ko J, Thayer W, Greenberg J, et al. Use of processed allografts to repair nerve injuries greater than 25 mm in the hand. Ann Plast Surg. 2017;78(6 Suppl 3):S292–S55.

25. Kaplan HM, Mishra R, Kohn J. The overwhelming use of rat models in nerve regeneration research may compromise designs of nerve guidance conduits for humans. J Mater Sci Mater Med. 2015;26(8):226.

26. Bozkurt A, Boecker A, Tank J, Altinova H, Deumens R, Dabhi K, et al. Processed nerve allografts for peripheral nerve reconstruction: a pilot clinical study in rats. Ulus Travma Acil Cerrahi Derg. 2016;22(1):1–11.

27. Fitzgerald TA. Comparison of research cost: man—primate models—other animal models. J Med Primatol. 1983;12(3):138–45.

28. Varejao AS, Meek MF, Ferreira AJ, Patricio JA, Cabrita AM. Functional evaluation of peripheral nerve regeneration in the rat: walking track analysis. J Neurosci Methods. 2001;108(1):1–9.

29. Hadlock TA, Sundback CA, Hunter DA, Vacanti JP, Cheney J, et al. The influence of the graft length on the functional outcome in sensory, mixed, and motor nerve reconstructions. Microsurgery. 2009;18(7):397–405.

30. Hadlock TA, Sundback CA, Hunter DA, Vacanti JP, Cheney ML. A new artificial nerve graft containing rolled Schwann cell monolayers. Microsurgery. 2001;21(3):96–101.

31. Hood B, Levene HB, Levi AD. Transplantation of autologous Schwann cells for the repair of segmental peripheral nerve defects. Neurosurgery. 2003;196:176–96.

32. Konofaos P, Ver Halen JP. Nerve repair by means of tubulation: past, present, future. J Reconstr Microsurg. 2013;29(3):149–64.

33. Isaacs J, Browne T. Overcoming short gaps in peripheral nerve repair: conduits and human acellular nerve allograft. Hand (NY). 2014;9(2):131–7.

34. Meek ME, Coert JH. Clinical use of nerve conduits in peripheral-nerve repair: review of the literature. J Reconstr Microsurg. 2002;18(2):97–109.

35. Konofaos P, Ver Halen JP. Nerve repair by means of tubulation: past, present, future. J Reconstr Microsurg. 2013;29(3):149–64.

36. Kusaba H, Terada-Nakaishi M, Wang W, Itoh S, Nozaki K, Nagai A, et al. Comparison of nerve regenerative efficacy between decellularized nerve graft and nonwoven chitosan conduit. Biomater Eng. 2016;27(1):75–85.

37. Ozkan HS, Karatas Silistreli O, Ergur B, Irkoren S. Repairing peripheral nerve defects by vein grafts filled with adipose tissue derived stromal vascular fraction: an experimental study in rats. Ulus Travma Acil Cerrahi Derg. 2016;22(1):1–11.

38. Neubauer D, Graham JB, Muir D. Chondroitinase treatment increases the effective length of acellular nerve grafts. Exp Neurol. 2007;207(1):163–70.

39. Radtke C, Akiyama Y, Lankford KL, Vogt PM, Krause DS, Kocsis JD. Integration of engrafted Schwann cells into injured peripheral nerve: axonal association and nodal formation on regenerated axons. Neurosci Lett. 2005;387(2):85–9.

40. Roesner H, et al. Long nerve gaps limit the regenerative potential of bioartificial nerve conduits filled with Schwann cells. Restor Neurol Neurosci. 2007;25(2):131–41.

41. Kirk AD. Crossing the bridge: large animal models in translational transplantation research. Immunol Rev. 2003;196:176–96.

42. Konofaos P, Ver Halen JP. Nerve repair by means of tubulation: past, present, future. J Reconstr Microsurg. 2013;29(3):149–64.

43. Straub B, Rodríguez DM, Díaz J, Yu HL, Kaplan G, Weinstein DE. Autologous Schwann cells drive regeneration through a 6-cm autogenous venous nerve conduit. J Reconstr Microsurg. 2001;17(8):589–95, discussion 596–7.

44. Straub B, Ferder M, Lovelle-Allen S, Moore K, Kim DJ, Llena J. Determining the maximal length of a vein conduit used as an interposition graft for nerve regeneration. J Reconstr Microsurg. 1996;12(8):521–7.

45. Ferrer M, Lovelle-Allen S, Moore K, Kim DJ, Llena J. Determining the maximal length of a vein conduit used as an interposition graft for nerve regeneration. J Reconstr Microsurg. 1996;12(8):521–7.

46. Battistin B, Tos P, Cuschway TR, Geuna S. Nerve repair by means of vein filled with muscle grafts I. Clinical results. Microsurgery. 2000;20(1):32–6.

47. Norris R, Glaab M, Gattuso J, Bowden R. Peripheral nerve repair in humans using muscle autografts. Anewtechnique. Bone Joint J. 1988;70-B(4):539–3.

48. Radtke C, Akiyama Y, Lankford KL, Vogt PM, Krause DS, Kocsis JD. Integration of engrafted Schwann cells into injured peripheral nerve: axonal association and nodal formation on regenerated axons. Neurosci Lett. 2005;387(2):85–9.

49. Frostick SP, Yin Q, Kemp GJ. Schwann cells, neurotrophic factors, and peripheral nerve regeneration. Microsurgery. 1998;18(7):397–405.

50. Scheib J, Hoke A. Advances in peripheral nerve regeneration. Nat Rev Neurol. 2013;9(12):668–76.

51. Hadlock TA, Sundback CA, Hunter DA, Vacanti JP, Cheney ML. A new artificial nerve graft containing rolled Schwann cell monolayers. Microsurgery. 2001;21(3):96–101.

52. Hadlock TA, Sundback CA, Hunter DA, Vacanti JP, Cheney ML. A new artificial nerve graft containing rolled Schwann cell monolayers. Microsurgery. 2001;21(3):96–101.

53. Kirk AD. Crossing the bridge: large animal models in translational transplantation research. Immunol Rev. 2003;196:176–96.

54. Battistin B, Tos P, Cuschway TR, Geuna S. Nerve repair by means of vein filled with muscle grafts I. Clinical results. Microsurgery. 2000;20(1):32–6.

55. Konofaos P, Ver Halen JP. Nerve repair by means of tubulation: past, present, future. J Reconstr Microsurg. 2013;29(3):149–64.
Nerve grafting for peripheral nerve injuries with extended defect sizes

...and electrophysiological evaluation of regenerated nerves. Brain Res. 2000;868(2):315–28.

...of woven spider silk meshes during remodeling in a rodent fascia replacement model. Ann Surg. 2014;259(4):781–92.

...promote peripheral nerve regeneration. Cell Prolif. 2006;39(1):40–7.

...silk fibres in artificial nerve conduits for nerve gaps up to 5 cm in the primate. J Reconstr Microsurg. 1999;6(2):117–21.

...in vivo. 2002;16(4):229–34.

...and collagen fibres—versatile biomaterials for tissue engineering and medical applications. Biomater. 2011;32(15):4088–97.

...and collagen fibres. Biomaterials. 2003;24(18):401–16.

...of woven spider silk meshes during remodeling in a rodent fascia replacement model. Ann Surg. 2014;259(4):781–92.

...promotes peripheral nerve regeneration. Cell Prolif. 2006;39(1):40–7.

...silk fibres—versatile biomaterials for tissue engineering and medical applications. Biomater. 2011;32(15):4088–97.
paradigm in regenerative medicine. J Cell Mol Med. 2009;13(11–12):4385–402.

96. Wiseman AC. Immunosuppressive medications. Clin J Am Soc Nephrol. 2015;11(2):332–43.

97. Barbour JR, Yee A, Moore AM, Trulock EP, Buchowski JM, Mackinnon SE. Cadaveric nerve allotransplantation in the treatment of persistent thoracic neuralgia. Ann Thorac Surg. 2015;99(4):1414–7.

98. Cohen DJ, Loertscher R, Rubin ME, Tilney NL, Carpenter CB, Strom TB. Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med. 1984;101(5):667–82.

99. Matsuyama T, Midha R, Mackinnon SE, Munro CA, Wong PY, Ang LC. Long nerve allografts in sheep with Cyclosporin A immunosuppression. J Reconstr Microsurg. 2000;16(3):219–25.

100. Shahraki M, Mohammadi R, Najafpour A. Influence of tacrolimus (FK506) on nerve regeneration using allografts: a rat sciatic nerve model. J Oral Maxillofac Surg. 2015; https://doi.org/10.1016/j.joms.2015.03.032.

101. Brenner MJ, Lowe JB 3rd, Fox IK, Mackinnon SE, Hunter DA, Darcy MD, et al. Effects of Schwann cells and donor antigen on long-nerve allograft regeneration. Microsurgery. 2005;25(1):61–70.

102. Jensen JN, Brenner MJ, Tung TH, Hunter DA, Mackinnon SE. Effect of FK506 on peripheral nerve regeneration through long grafts in inbred swine. Ann Plast Surg. 2005;54(4):420–7.

103. Ide C, Tohyama K, Tajima K, Endoh K, Sano K, Tamura M, et al. Long acellular nerve transplants for allogeneic grafting and the effects of basic fibroblast growth factor on the growth of regenerating axons in dogs: a preliminary report. Exp Neurol. 1998;154(1):99–112.

104. US Food and Drug Administration. US food and drug administration medical device database available via DIALOG. https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Databases/default.htm. Accessed 02.2018.